Mehmet Bakırtaş

4PUBLICATIONS
21CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Apr 27, 2026
Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin's Lymphoma: A Multi-Center Retrospective Study on Survival and Safety.

|Mar 14, 2026
Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey.

Mehmet Bakırtaş, İlhami Berber, İpek Yönal Hindilerden

|May 22, 2023
Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey.

Mehmet Bakırtaş, Mehmet Sinan Dal, Tuğçe Nur Yiğenoğlu

|Nov 25, 2020
Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

Hikmettullah Batgi, Semih Başcı, Mehmet Sinan Dal

Pageof 1

Frequent Collaborators

1 joint publications

Hikmettullah Batgi

1 joint publications

Semih Başcı

1 joint publications

Mehmet Sinan Dal

1 joint publications

Merih Kızıl Çakar